UPDATE 1-Cerus to regain Asian rights for blood safety system

* To acquire marketing rights from Asian partner BioOne

* BioOne to get about 1.2 mln Cerus shares at $3.08/shr

* Cerus to relinquish equity interest in BioOne

Aug 24 (BestGrowthStock) – Cerus Corp (CERS.O: ) said it will take
back the marketing rights for its blood safety system from its
Asian partner BioOne Corp, for about $3.6 million.

Under the agreement, BioOne, a Japanese medical device
company, will get about 1.2 million shares of Cerus at about
$3.08 per share, and Cerus will relinquish its equity interest
in BioOne.

Cerus licensed the marketing rights for Intercept
platelets and plasma to BioOne in countries including China,
Japan, Taiwan, Singapore, Korea, Thailand and Vietnam in 2004
and 2005.

Cerus holds the marketing rights for the Intercept red
blood cell system for this region.

The Intercept blood system inactivates blood-borne
pathogens such as viruses, bacteria and parasites in donated
blood and blood components that are intended for transfusion.

The deal will allow Cerus to consolidate worldwide rights
to Intercept platelets, plasma and red blood cells, the company

The Concord, California-based company’s shares, which have
gained 44 percent over the past one year, closed at $2.92
Tuesday on Nasdaq.
(Reporting by Krishnakali Sengupta in Bangalore;)

UPDATE 1-Cerus to regain Asian rights for blood safety system